157 related articles for article (PubMed ID: 33112552)
1. Cyclin D1 G870A Polymorphism: Relation to the Risk of ALL Development, Prognosis Impact, and Methotrexate Cytotoxicity.
El Menshawy N; El Marghany AB; Sarhan MM; Aladle DA
Asian Pac J Cancer Prev; 2020 Oct; 21(10):2941-2947. PubMed ID: 33112552
[TBL] [Abstract][Full Text] [Related]
2. CCND1 G870A polymorphism is associated with toxicity of methotrexate in childhood acute lymphoblastic leukemia.
Xue Y; Rong L; Tong N; Wang M; Zhang Z; Fang Y
Int J Clin Exp Pathol; 2015; 8(9):11594-600. PubMed ID: 26617896
[TBL] [Abstract][Full Text] [Related]
3. Association of cyclin D1 A870G polymorphism with two malignancies: acute lymphoblastic leukemia and breast cancer.
Bedewy AM; Mostafa MH; Saad AA; El-Maghraby SM; Bedewy MM; Hilal AM; Kandil LS
J BUON; 2013; 18(1):227-38. PubMed ID: 23613410
[TBL] [Abstract][Full Text] [Related]
4. CCND1 G870A polymorphism and cervical cancer risk: a case-control study and meta-analysis.
Ni J; Wang M; Wang M; Fu S; Zhou D; Zhang Z; Han S
J Cancer Res Clin Oncol; 2011 Mar; 137(3):489-94. PubMed ID: 20473525
[TBL] [Abstract][Full Text] [Related]
5. CCND1 G870A polymorphism with altered cyclin D1 transcripts expression is associated with the risk of glioma in a Chinese population.
Chen X; Zhao T; Li L; Xu C; Zhang X; Tse V; Zhang T; Liu X; Lu F
DNA Cell Biol; 2012 Jun; 31(6):1107-13. PubMed ID: 22304571
[TBL] [Abstract][Full Text] [Related]
6. Association between cyclin D1 (CCND1) G870A polymorphism and gastric cancer risk: a meta-analysis.
Zhang Y; Zeng X; Lu H; Ji H; Zhao E; Li Y
Oncotarget; 2016 Oct; 7(40):66109-66118. PubMed ID: 27623072
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 G870A polymorphism and the risk of hepatocellular carcinoma in a Chinese population.
Hu Z; Zhou Z; Xiong G; Wang Y; Lai Y; Deng L; Yang J
Tumour Biol; 2014 Jun; 35(6):5607-12. PubMed ID: 24570185
[TBL] [Abstract][Full Text] [Related]
8. Lack of evidence for predictive and prognostic value of cyclin D1 gene polymorphism CCND1 G870A for oral squamous cell carcinoma.
Atac A; Riecke B; Assaf AT; Gröbe A; Friedrich RE; Heiland M; Izbicki JR; Kluwe L; Blessmann M
Anticancer Res; 2014 Jan; 34(1):235-8. PubMed ID: 24403468
[TBL] [Abstract][Full Text] [Related]
9. Cyclin D1 G870A polymorphism and risk of nasopharyngeal carcinoma: a case-control study and meta-analysis.
Liao D; Wu Y; Pu X; Chen H; Luo S; Li B; Ding C; Huang GL; He Z
PLoS One; 2014; 9(11):e113299. PubMed ID: 25409185
[TBL] [Abstract][Full Text] [Related]
10. Potential role of CCND1 G870A genotype as a predictor for urothelial carcinoma susceptibility and muscle-invasiveness in Taiwan.
Lin HH; Ke HL; Hsiao KH; Tsai CW; Wu WJ; Bau DT; Chang LL
Chin J Physiol; 2011 Jun; 54(3):196-202. PubMed ID: 21789902
[TBL] [Abstract][Full Text] [Related]
11. [Correlation analysis of G870A CCND1 gene polymorphism with digestive system tumors].
Yang SM; Shi YL
Nan Fang Yi Ke Da Xue Xue Bao; 2016 Nov; 36(11):1589-1592. PubMed ID: 27881356
[TBL] [Abstract][Full Text] [Related]
12. Cyclin D1 gene (CCND1) polymorphism and the risk of squamous cell carcinoma of the larynx.
Rydzanicz M; Golusinski P; Mielcarek-Kuchta D; Golusinski W; Szyfter K
Eur Arch Otorhinolaryngol; 2006 Jan; 263(1):43-8. PubMed ID: 16258756
[TBL] [Abstract][Full Text] [Related]
13. Cyclin D1 G870A polymorphism is associated with risk and clinicopathologic characteristics of bladder cancer.
Yuan L; Gu X; Shao J; Wang M; Wang M; Zhu Q; Zhang Z
DNA Cell Biol; 2010 Oct; 29(10):611-7. PubMed ID: 20575692
[TBL] [Abstract][Full Text] [Related]
14. AA genotype of cyclin D1 G870A polymorphism increases breast cancer risk: Findings of a case-control study and meta-analysis.
Akhter N; Alzahrani FA; Dar SA; Wahid M; Sattar RSA; Hussain S; Haque S; Ansari SA; Jawed A; Mandal RK; Almalki S; Alharbi RA; Husain SA
J Cell Biochem; 2019 Oct; 120(10):16452-16466. PubMed ID: 31243808
[TBL] [Abstract][Full Text] [Related]
15. Cyclin D1 gene polymorphism and susceptibility to childhood acute lymphoblastic leukemia in a Chinese population.
Hou X; Wang S; Zhou Y; Xu Z; Zou Y; Zhu X; Han M; Pang T; Han ZC
Int J Hematol; 2005 Oct; 82(3):206-9. PubMed ID: 16207592
[TBL] [Abstract][Full Text] [Related]
16. Cyclin D1 G870A polymorphism and breast cancer risk: a meta-analysis involving 23,998 subjects.
Yang J; Liu H; Lu S; Gao M; Du Q; Tang SC
Oncol Res; 2011; 19(12):519-25. PubMed ID: 22812184
[TBL] [Abstract][Full Text] [Related]
17. Tumor susceptibility and prognosis of breast cancer associated with the G870A polymorphism of CCND1.
Yu CP; Yu JC; Sun CA; Tzao C; Ho JY; Yen AM
Breast Cancer Res Treat; 2008 Jan; 107(1):95-102. PubMed ID: 18043898
[TBL] [Abstract][Full Text] [Related]
18. Pharmacogenomic Markers of Methotrexate Response in the Consolidation Phase of Pediatric Acute Lymphoblastic Leukemia Treatment.
Kotur N; Lazic J; Ristivojevic B; Stankovic B; Gasic V; Dokmanovic L; Krstovski N; Milosevic G; Janic D; Zukic B; Pavlovic S
Genes (Basel); 2020 Apr; 11(4):. PubMed ID: 32344632
[TBL] [Abstract][Full Text] [Related]
19. Cyclin D1 G870A polymorphism and lung cancer risk: a meta-analysis.
Liu J; Liao Q; Zhang Y; Sun S; Zhong C; Liu X
Tumour Biol; 2012 Oct; 33(5):1467-76. PubMed ID: 22528945
[TBL] [Abstract][Full Text] [Related]
20. The influence of cyclin D1 (CCND1) 870A>G polymorphism and CCND1-thymidylate synthase (TS) gene-gene interaction on the outcome of childhood acute lymphoblastic leukaemia.
Costea I; Moghrabi A; Krajinovic M
Pharmacogenetics; 2003 Sep; 13(9):577-80. PubMed ID: 12972956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
